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Abstract 
This module reflected work within the Group for Research and Assessment of Psoriasis and 
Psoriatic Arthritis (GRAPPA) to develop and validate composite disease activity measures in 
PsA. At OMERACT 8, a core set of domains to be assessed in randomized controlled trials 
(RCTs) and longitudinal observational studies (LOS) of psoriatic arthritis (PsA) was agreed 
upon.  At OMERACT 10, five proposed composite responder definitions for PsA were 
reviewed and discussed including new data from the GRACE (GRAppa Composite Exercise) 
study.  At OMERACT 11, ongoing retrospective analyses of RCT data using the three 
proposed measures (the CPDAI[Composite Psoriatic Disease Activity Index], PASDAS 
[Psoriatic ArthritiS Disease Activity Score] and AMDF [Arithmetic Mean of the Desirability 
Function]) were discussed in detail. 
 
There was agreement that developing composite outcome measures for use in RCTs and LOS 
in PsA was important. Concerns were expressed regarding development of a single measure 
that encompassed diverse domains such as joint counts, quality of life and disability 
measures. It was emphasized that the use of any composite measure should include the ability 
to differentiate between activity in individual domains, such as enthesitis or psoriasis, such 
that the impact of each could be assessed independently. It was also agreed that patients 
would be systematically involved in further development and refinement of composite 
measures. 
 
Future work planned includes qualitative work with patients to explore their experience of 
disease activity and statistical modeling to explore how each of the proposed measures will 
perform in different disease subgroups. 
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Short Running Footline 
OMERACT psoriatic arthritis module 2012 
  
Introduction: 
Psoriatic arthritis (PsA) is a multi-faceted disease with involvement of peripheral joints, skin, 
nails, entheses, soft tissues of the digits (i.e., dactylitis) and axial skeleton.  Outcomes 
research in PsA has generally lagged behind that in rheumatoid arthritis (RA). The lack of 
validated outcome measures comprising all domains of disease involvement in PsA remains a 
particular challenge.  Many different outcome measures for each of the separate aspects of 
the disease are available but most are borrowed from related diseases such as RA, axial 
spondyloarthritis, (AxSpa), or psoriasis and only some have been validated in PsA.  Until 
recently there were no composite outcome measures for PsA that included all of the 
mentioned aspects of disease involvement. 
 
Composite measures used in RA to assess disease severity and employed in responder 
indices, such as the Disease Activity Score (DAS) with the related European League Against 
Rheumatism (EULAR) Response Criteria, or the American College of Rheumatology (ACR) 
Response Criteria, primarily focus on the assessment of peripheral joint activity.  The DAS 
includes an acute phase response marker and ACR response criteria include acute phase 
response, pain, and physical function in addition to specific measures of peripheral arthritis 
but these do not fully represent all aspects of PsA.  While used in many RCTs to assess 
peripheral joint disease activity and indirectly, through the patient global assessment, other 
aspects of PsA, these composite measures omit direct evaluation of the additional domains of 
PsA such as enthesitis, dactylitis, axial and skin disease.  
 
Recognition of this dearth of validated outcome measures in PsA led to the formation of a 
joint Outcome Measures in Rheumatology (OMERACT)/Group for Research and 
Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) working group to develop a 
research agenda of outcome measurement in randomized controlled trials (RCTs) in PsA.  
There are currently more than 400 members of GRAPPA internationally, including 
rheumatologists, dermatologists, radiologists, epidemiologists, industry and patient service 
league representatives. 
 
The first step was an outcome measures workshop in PsA held at OMERACT 7 (Asilomar, 
USA, 2004).  Discussion on potential domains for inclusion in RCTs in PsA led to a research 
agenda to identify optimal measures for each aspect of psoriatic disease and to develop 
effective instruments where none existed (1).  Significant further progress was made at the 
OMERACT 8 conference (Malta, 2006) . There, consensus was reached on the core domain 
set for PsA trials(2), based on a series of projects conducted following OMERACT 7 
including: a clinician Delphi exercise and data mining from completed RCTs.  At 
OMERACT 8, no data were available on composite measures designed to assess multiple 
domains of PsA. 
 
Since OMERACT 8, GRAPPA has been actively working to develop reliable diagnostic and 
assessment tools for PsA, including clinical, laboratory, imaging, tissue analysis, and 
composite measures of disease activity. This work is pursued both in individual clinical 
research centers as well as collaboratively amongst members of the group. At the GRAPPA 
Annual Meeting in 2008 (Leeds, UK) data from application of previously, work on different 
proposed composite indices were presented, including many of the measures discussed 
below.  Different potential approaches were also discussed, e.g., the development of the DAS 
in RA and the Ankylosing Spondylitis Disease Activity Score (ASDAS) as well as the British 
Isles Lupus Assessment Group (BILAG) score in systemic lupus erythematosus(4).  Breakout 
groups discussed these different options and a large collaborative exercise (GRACE) was 
proposed to initiate the development and validation of a GRAPPA/OMERACT composite 
disease activity measure for PsA(5).  This work led to a special interest group (SIG) at 
OMERACT 10 being convened in 2010.  At this session results of ongoing work with the 
GRACE dataset and analysis of some proposed composite measures was presented. 
 
Proceedings during the Module 
At OMERACT 11 a literature review of measures used in PsA was presented to summarise 
existing individual measures designed to assess varying aspects of disease.  An individual 
with PsA spoke about her experiences of developing PsA and the myriad ways her disease 
has affected her, highlighting the importance of measuring domains other than just articular 
or skin disease.  Oliver FitzGerald presented a summary of the evidence supporting use of the 
Composite Psoriasis Disease Activity Index (CPDAI) including a recent analysis from the 
Psoriasis Randomised Etanercept Study in Subjects with Psoriatic Arthritis (PRESTA) data.  
Philip Helliwell presented the methodology for development of the Psoriatic Arthritis Disease 
Activity Score (PASDAS), a weighted composite measure analogous to the DAS in RA, and 
for the Arithmetic Mean of the Desirability Function (AMDF), a non-weighted score where 
all variables are transformed to the same scale and combined arithmetically.  Finally 
discussion with participants at OMERACT was designed to highlight issues and 
methodologic points regarding development of the composite measures proposed to date. 
 
Background and Aims of the module 
Philip Mease provided a brief summary of the domains considered important in RCTs in PsA, 
as decided at OMERACT 8.  He highlighted different types of composite outcome measures 
in terms of design, and summarized the argument for a comprehensive composite index in 
PsA. He briefly reviewed work and introduced the aims of the module at OMERACT 11, 
namely: 
1. Present a literature review of various outcome measures that individually reflect different 
domains of PsA, and compare them with other composite measures of disease activity in RA 
as well 
2. Highlight the patient’s perspective with an illustration of the many ways in which this 
disease can affect a single patient over time. 
3. Present work to date assessing performance of the proposed PsA responder indices in 
datasets from completed RCTs and independent populations. 
4.  Provide a forum for discussion of these proposals and an opportunity for feedback and 
debate. 
5.  Define issues which remain in the research agenda regarding domains and instruments for 
their assessment in PsA. 
 
Review of outcome measures used in PsA clinical trials 
A number of outcome measures have been developed and used in PsA to measure different 
aspects of the disease (2, 6-11) (Table 1).   
For arthritis, the majority of measures used in RCTs in PsA were adopted from RA.  Dr 
Laura Coates summarized data regarding the use of ACR and DAS outcomes in PsA, 
explaining that these measures had been shown demonstrated responsive in polyarticular PsA 
as evident from differing clinical trial datasets (3). Deficiencies included that 28-joint counts 
are not reliable in PsA and there are no data concerning the validity of these measures in 
oligoarthritis.  The Psoriatic Arthritis Response Criteria (PsARC) was the first composite 
measure designed specifically for PsA in an RCT of sulfasalazine in PsA by Clegg, et al. and 
utilizes a composite measure of tender and swollen joint counts with patient and physician 
global assessments of disease activity(12).  However, it was empirically derived and does not 
specifically incorporate other features of PsA such as enthesitis, dactylitis, or axial or skin 
disease.  The use of the physician and patient global visual analogue scale (VAS) scores may 
partially reflect activity in these elements of disease depending on the wording of the VAS 
questions. 
 
A brief summary of new articular composite measures specifically designed for PsA was 
presented, i.e., the PsA Joint Activity Index (PsAJAI) and the Disease Activity in PSoriatic 
Arthritis (DAPSA).  Both scores have specifically excluded skin disease activity, although for 
different reasons. The PsAJAI,a response measure using a 30% reduction in disease activity 
as the cut-off, was developed from and tested in two independent samples from RCT datasets 
of tumor necrosis factor (TNF) inhibitors utilizing statistical modeling. Therefore, it has been 
validated in a predominantly polyarticular, not oligoarticular, subset of disease. It ultimately 
excluded a measure of skin disease activity because the magnitude of skin disease 
improvement in these trials was so large that it overwhelmed responses in articular 
disease(13).  The DAPSA score(14) was suggested for PsA after principal component 
analysis of data in 105 PsA patients found that the key disease domains were represented by 
measures included in the DAREA (Disease Activity index for Reactive Arthritis), originally 
developed for reactive arthritis(15).  In this analysis, skin disease activity was proposed as a 
component but did not quite reach significance, possibly due to the low level of skin disease 
in this specific patient cohort. Components of the DAREA include swollen and tender joint 
counts, patient global score, pain score and C-reactive protein (CRP). Ultimately, both the 
PsAJAI and the DAPSA have included only specific measures of articular disease although 
the global patient reported scores for disease activity and pain may partially encompass other 
elements of PsA but it unclear to what extent.   
To measure psoriasis, several skin measures have been developed for use in psoriasis RCTs 
and LOS. Interestingly, patients enrolled in PsA clinical trials often have low body surface 
area (BSA) involvement of psoriasis and thus may not be reliably evaluated with the Psoriasis 
Area and Severity Index (PASI) score(16). The PASI exhibits poorer performance in subjects 
with less than 3% BSA involvement. A “target lesion” score may be used, where one lesion is 
evaluated over the course of the study(6), but this does not reflect the total extent of disease 
involvement nor which areas are involved. Newer scoring methods such as the lattice system 
Physician’s Global Assessment of psoriasis (PGA)(17) and the Copenhagen Psoriasis 
Severity Index(18) were also briefly discussed.  Nail involvement is also a common problem 
in psoriasis and particularly in PsA.  The Psoriasis Nail Severity Score (PNSS), developed in 
Bath(19) has been utilized in studies and even more recently, several PsA trials have 
successfully incorporated a modified Nail Psoriasis Severity Index (mNAPSI) score for 
evaluation of responses in nail involvement(20).     
 
Recognizing the importance of enthesitis and dactylitis as domains, measures for these 
clinical features have evolved over the past several years and are now routinely performed. 
Several measures of enthesitis, which assess different groups of entheseal insertion sites, are 
being utilized and it is anticipated that as these are evaluated, a single measure may emerge 
as standard for PsA.  Measures specifically developed for PsA such as the Leeds Enthesitis 
Index (LEI) and developed in a mixed group of spondyloarthritis (SpA) patients, such as the 
SPARCC (Spondyloarthritis Research Consortium of Canada) enthesitis index are now being 
used in ongoing research.  These have identified different entheseal points that may be more 
important in PsA in comparison with older measures such as the Maastricht Ankylosing 
Spondylitis Enthesitis Score (MASES).  As part of the GRACE dataset, all clinical entheseal 
points in any of the accepted enthesitis indices are evaluated which is allowing assessment of 
how the different measures compare in a heterogenous real-world cohort and whether a new 
measure with a greater validity can be developed.  It was highlighted that up to half of 
patients with PsA experience dactylitis as some point in their disease course.  Measurement 
of this phenomenon has been evaluated by Helliwell et al who have compared existing 
measures such as digit counts and semi-quantitative scoring of dactylitis and have developed 
the dactylometer which allows quantification of clinical digit swelling(21, 22).  
 
Spinal involvement in PsA has generally been under-researched with no specific clinical 
trials in this group of patients.  Spinal involvement is not commonly measured in RCTs in 
PsA, partly due to difficulties assessing this disease component.  Physical examination 
measures of the spine are reliable in axial PsA(23) and reflect not only disease activity but 
also significant cumulative damage.  Measures of axial disease activity used in AxSpa, 
including the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and ASDAS 
have been shown to correlate with constructs of disease activity in axial PsA(24-26), but not 
to differentiate between peripheral and axial disease activity casting doubt on their construct 
validity in PsA. 
 
A patient’s perspective 
Next, a patient representative provided valuable perspective as an individual with PsA, but 
also as a physician who treats PsA and conducts research in PsA.  Highlights of the 
presentation included discussion about the initial symptoms which were primarily axial and 
entheseal and although she visited a rheumatologist early in her disease course, she came 
away without a diagnosis as no significant arthritis or skin disease was present at onset and 
initial laboratory assessments and radiographs were negative. However, she understood as a 
rheumatologist what her symptoms meant before her treating rheumatologist did -- .. 
Cognizant of the United States’ health care system issues around pre-existing conditions and 
to avoid negative repercussions on her ability to provide for her family, obtain life insurance 
for her family as she was the primary breadwinner, she didn’t return for diagnosis or 
treatment when synovitis developed about 1 to 2 months later.  Instead, she reported she 
chose to self-manage the disease with minocycline and ibuprofen.  She originally thought she 
had AS, but once she developed onycholysis of her large toenails developed about 6 months 
into her symptoms, she recognized she most likely had PsA. She shared that the axial 
symptoms and fatigue had been some of the her worst symptoms, and that she also changed 
jobs to minimize the impact of stress, travel, and lack of sleep on her health. She recognized 
in herself complaints that her patients had made to her about, e.g., walking on marbles related 
to metatarsal pain, hobbling to the bathroom in the morning due to stiffness, keeping nail 
polish on her toenails to avoid showing evidence of her onycholysis. She appreciated the 
ability to better comprehend her patients’ complaints though suffering from them herself. She 
also recognized several issues specific to her that her patients had never mentioned: e.g., 
severe tailbone pain so severe that it made it difficult to sit for more than 30 minutes; or neck 
pain that made her consider where she sat in a room so she wouldn’t have to look up at the 
stage, turn her head or look up, spend a small fortune on different types of neck pillows, or 
carry her stethoscope over her shoulder instead of around her neck. Eventually, she returned 
to her rheumatologist who recognized her reluctance to start a TNF inhibitor, and he 
prescribed sulfasalazine.  She was thrilled as was her rheumatologist when she reported how 
well sulfasalazine had worked for her symptoms, especially the stiffness and peripheral joint 
disease. She mentioned that stress and lack of sleep continued to precipitate flares, and she 
has made it a priority to manage these.  She recognized that sulfasalazine has probably been a 
temporizing measure as it has not worked as well for her axial symptoms or nail disease as it 
has for her peripheral disease. Her disease and its impact on her and her family life were 
evolving and her therapy and disease would evolve with her. Ultimately, she stressed that as a 
researcher and physician as well as a patient, the currently available tools available did not 
accurately assess the impact of PsA on her disease or her life.   
 
Current proposed composite outcome measures – the CPDAI 
Work developing two key composite measures has been initiated and led by members of 
GRAPPA. FitzGerald and colleagues developed a composite outcome measure based on the 
GRAPPA treatment grid published by Ritchlin, et al(27).  For the CPDAI,  a score of 0-3 is 
assigned to each of the five domains (arthritis, enthesitis, dactylitis, skin and spinal disease) 
of PsA based on disease activity and impact of disease for this domain (Table 2).  The scores 
are added together to give a total score of 0-15, thus providing an overall assessment of 
disease activity(28).  One concern raised during the development of this measure was that 
patients with severe disease activity in only one domain may be disadvantaged by a relatively 
low total score.  Two potential solutions have been proposed: first that anyone with a single 
domain scored as severe would be classified as “severe” overall; second a “modified 
CPDAI”, where the total score is divided by the number of active domains involved yielding 
a mean score.   
 
Oliver FitzGerald presented validation data for CPDAI from analysis of the PRESTA data.  
Because PRESTA was an RCT comparing two doses of etanercept (50mg each week and 
50mg twice weekly) in a large number of patients with both active psoriasis and PsA(29), it 
provides an ideal dataset with which to assess the sensitivity of composite disease activity 
measures.  Supporting evidence was that individual measures of joint disease, enthesitis and 
dactylitis showed similar changes between higher and lower doses of etanercept, but a 
superior response was evident with the higher dose for skin disease.  There were a few 
limitations of this dataset.  Like many RCTs of PsA, the majority of patients had polyarticular 
disease despite not being an inclusion criterion, so this dataset does not provide evidence for 
responsiveness of these measures in oligoarthritis.  Like many RCTs in PsA, there was no 
specific assessment or measure of axial disease in this trial.  For this reason, a modified 
CPDAI assessing four domains (peripheral joint disease, skin, dactylitis and enthesitis) was 
scored from 0-12 rather than 0-15. 
 
The CPDAI showed good responsiveness to change and identified a significant difference 
between treatment groups at 12 weeks that was likely driven by the differential response in 
skin disease (p=0.049). In stepwise regression analysis, enthesitis, the Health Assessment 
Questionnaire (HAQ), dactylitis and the Dermatology Life Quality Index (DLQI) all 
contributed significantly to the CPDAI values at baseline(30). In comparison, the DAPSA 
score showed a significant improvement between baseline and 12 weeks in both treatment 
groups but did not identify a significant difference between the treatment groups at week 12.  
Thus, while both the DAPSA and CPDAI show responsiveness in measures of arthritis, the 
CPDAI has a potential advantage in that it can also reflect changes in the other domains of 
PsA. 
 
GRACE  
Following the GRAPPA annual meeting in 2008 and as part of the preparation for 
OMERACT 10, GRAPPA initiated GRACE which aimed to develop an inclusive composite 
outcome measure based on real patient data.  Longitudinal observational data were collected 
on a large cohort of PsA patients internationally.  Individual outcomes assessing disease 
activity in all of the domains of PsA, as well as patient reported outcome measures are being 
collected.  Where no consensus had been reached regarding optimal outcome measures for 
each component of disease, e.g. enthesitis, multiple measures were collected to allow 
comparison of different indices.  Patients were classified by their treating physician into two 
groups: those with active disease requiring a treatment change and patients who in the 
opinion of their treating physician have low disease activity or are in remission.  The two 
groups were then be compared to see where significant differences exist between them and 
which individual outcome measures account for this difference. 
 
Recruitment to GRACE completed with baseline data on 503 patients with PsA collected and 
follow up data also available.  Analysis of the many outcome measures included in the 
dataset has shown a difference in all key variables encompassing arthritis, skin disease, 
enthesitis, dactylitis, axial disease, functional ability and quality of life for those undergoing 
treatment change and those not, except for the mNAPSI, Maastricht Ankylosing Spondylitis 
Enthesitis Score (MASES), erythrocyte sedimentation rate (ESR) and Bath Ankylosing 
Spondylitis Metrology Index (BASMI).   
 
Current proposed composite outcome measures – the PASDAS 
The first methodology pursued by the OMERACT PsA group was to develop a weighted 
composite disease activity score called the PASDAS utilizing methodology used to develop 
the DAS and ASDAS.  A principal component analysis was performed for all variables 
included in disease activity measures with transformation for all variables to improve variable 
distribution.  Factor analysis identified five components which were (1) patient and physician 
VAS scores of disease activity, (2) skin activity, (3) tender joint count and enthesitis, (4) 
swollen joint count and dactylitis, and (5) CRP.  However with regression analysis, nearly 
80% of variability (adjusted R2) was provided by the patient global disease visual analog 
scale (VAS) and over 90% by just three VAS scores (patient global assessment, patient 
assessment of skin disease, and physician global assessment) using the Cauli standardized 
VAS questions for PsA(31).  At OMERACT 10 and at a later GRAPPA meeting adjacent to 
EULAR 2010, Philip Helliwell therefore proposed the Psoriatic Arthritis Disease Activity 
Score (PASDAS) as a composite of three VAS scores. Significant concern was voiced about 
using just three subjective VAS scores to measure disease activity, particularly by GRAPPA 
attendees from sponsors who felt that such a disease activity measure would not be supported 
by regulatory authorities as a robust tool. 
 
Following this discussion, a revised PASDAS was developed.  Principal component analysis 
revealed 7 components which approximated to the following domains: patient reported 
measures (excluding the mental component summary score [MCS] of the Medical Outcomes 
Survey Short form-36 [SF-36]), skin, peripheral joint counts, dactylitis, enthesitis, acute 
phase response and the SF-36 (MCS).  In the subsequent forward stepwise regression (FSR), 
two of the variables (patient and physician global VAS scores) accounted for approximately 
90% of the total variance in scores (as seen in the previous incarnation of the PASDAS). A 
hierarchical multiple regression analysis then considered these variables where both global 
VAS scores were entered in step 1, dactylitis, enthesitis, CRP, swollen joint count and SF-36-
PCS (the physical component summary score of the SF-36) in step 2, and finally tender joint 
count and SF-36 MCS (neither of which were significant in the FSR) in step 3. The SF-36 
MCS did not contribute to the model variance and was therefore omitted from the final 
PASDAS(32). 
 
The final PASDAS is represented by the following equation: 
PASDAS = (((0.18 x √Physician global VAS) + (0.159 x √Patient global VAS) - (0.253 x 
√SF36 - PCS) + (0.101 x LN (Swollen joint count + 1)) + (0.048 x LN (Tender joint count + 
1)) + (0.23 x LN (Leeds Enthesitis Index + 1)) + (0.377 LN (tender Dactylitis count + 1)) + 
(0.102 x LN (CRPmg/dL + 1)) +2)*1.5. 
 
Current proposed composite outcome measures – the AMDF 
The second approach was that suggested by Fransen et al(33), where desirability functions  
were developed for variables deemed important in assessing disease activity, based on core 
domains selected for PsA RCTs at OMERACT 8(2). The desirability function can be used to 
combine multiple responses into one measure by translating each variable onto the same scale 
from 0 (a completely unacceptable or undesirable level) to 1 (a completely desirable or ideal 
response value).  Then these transformed variables can be averaged to give a total score.  
Desirability functions for tender and swollen joint counts, HAQ and the patient global 
assessment of disease activity VAS were derived using expert consensus data gathered by an 
internet based survey of GRAPPA members during development of the minimal disease 
activity score(34). Remaining functions (patient VAS for skin, patient VAS for joints, PASI, 
and Psoriatic Arthritis Quality of Life index (PsAQoL) were developed with expert consensus 
data obtained from 109 responses in a subsequent internet survey (85 rheumatologists and 24 
dermatologists). Cut-offs were determined according to the median of responses (Table 2), 
and used to transform each variable into linear functions ranging from 0 (totally unacceptable 
state) to 1 (normal). The 8 transformed variables were then combined using the arithmetic 
mean (AMDF: arithmetic mean of desirability functions).   
 
Performance of the PASDAS and AMDF in RCT and Observational Cohort Datasets 
The OMERACT PsA group aimed to work with many different organizations to apply and 
test these proposed composite measures in existing RCT and observational cohort datasets 
prior to the OMERACT 11 module.  Unfortunately, many existing datasets do not include all 
the variables required to calculate the proposed composite measures.  There were also delays 
in obtaining RCT data for this purpose : only PRESTA data as discussed above were 
available.  A few unavailable variables, e.g., SF-36, PsAQoL, axial disease measures, 
resulted in minor modifications to calculations of the CPDAI, PASDAS and AMDF 
composite measures.  
 
All of the composite measures (DAPSA, CPDAI, PASDAS and AMDF) were compared 
using ANCOVA to compare effect sizes and DAS28 was included as a control measure.  The 
largest effect size was seen with the AMDF score (>2) with a significant difference between 
effect sizes in the two treatment regimens at 12 weeks.  Effect sizes for the CPDAI and 
PASDAS were also high (~1.5) with lower effect sizes seen with DAPSA and DAS28. 
 
Case Examples 
Case 1 
A 34 year old man who presented to rheumatology with a six year history of inflammatory 
back pain.  He had had skin psoriasis since childhood and also had active enthesitis affecting 
one Achilles tendon and both medial femoral condyles and lateral elbow epicondyles.  He did 
not have any peripheral arthritis or dactylitis.  He had been treated via his physician with 
physiotherapy and oral nonsteroidal anti-inflammatory drugs (NSAIDs) with no relief of 
symptoms. 
 
The elements of all of these scores are shown in table 2.  Using the CPDAI, this man scored 
as follows: Peripheral arthritis – 0, Skin disease – 2, Enthesitis – 2, Dactylitis – 0, Axial 
disease – 3.  His total CPDAI score was 7 indicating severe disease and he was started on a 
TNF inhibitor due to his severe spinal disease. When applying the PASDAS weighted score 
in this case, the total score was 6.03 indicating high disease activity under proposed cut-offs.  
Using the AMDF score, the total score was 0.53 (scale 0 to 1, 1 is no disease activity) 
indicating moderate disease activity according to cut-offs defined by Fransen et al (33).  The 
elements of all of these scores are shown in table 2.  Interestingly the absence of activity in 
one element of disease (peripheral arthritis) in this case causes a “perfect” score of 1 to be 
attributed to both tender and swollen joint counts in the AMDF which inflates the score 
reducing disease activity from high to moderate using this scoring method 
 
Case 2 
This 34 year old lady developed psoriasis at the age of 16 and was then diagnosed with PsA 
age 22.  At the time of this assessment, she was reviewed in a combined clinic and the plan 
was for her to start a TNF inhibitor.  She had active peripheral polyarthritis with dactylitis in 
4 toes.  She also had axial disease and active skin psoriasis with scattered plaques all over her 
body.  Using the CPDAI, this woman scored a total of 10 indicative of severe disease: 
Peripheral arthritis – 3, Skin disease – 2, Enthesitis – 0, Dactylitis – 3, Axial disease – 2. 
When applying the PASDAS weighted score, the total score was 6.78 indicating high disease 
activity under proposed cut-offs.  Using the AMDF score, the total score was 0.46 which 
indicates moderate disease activity (33).  She was started on adalimumab due to her severe 
disease affecting both the peripheral and axial skeleton.  The elements of all her scores are 
shown in table 3. In this case, the absence of significant skin disease and a relatively low 
HAQ score decreased the AMDF score to be moderate rather than high as it was for the 
CPDAI and PASDAS, despite high disease activity in the joints. 
 
Case 3 
This 37 year old man had psoriasis since age 4 and then developed PsA at the age of 22.  He 
was also being assessed for anti-TNF therapy.  He had oligoarthritis affecting the left 1st 
metacarpophalangeal (MCP) joint and the right metatarsus.  He also had two enthesitis points 
and dactylitis of the left 4th toe. Given the different aspects of disease and his ongoing active 
disease, he was started on disease modifying anti-rheumatic drug (DMARD) therapy to 
control his arthritis and dactylitis.  The elements of all of this man’s scores are shown in table 
4. Using the CPDAI, this man had a total score of 3 indicative of mild disease: Peripheral 
arthritis – 1, Skin disease – 0, Enthesitis – 1, Dactylitis – 1, Axial disease – 0.  When 
applying the PASDAS weighted score in this case, the total score was 3.74 indicating 
moderate disease activity, while the AMDF indicated low disease activity with a score of 
0.86. 
 
Discussion at OMERACT 11 
At the start of the module, participants were asked to vote on two questions.  Firstly, they 
were asked “Are existing measures of composite disease activity developed for rheumatoid 
arthritis appropriate to measure disease activity/response in psoriatic arthritis?”.  Secondly 
they were asked “Do you think a composite measure that only measures inflammatory joint 
disease and not other musculoskeletal manifestions, nor the skin, is sufficient to measure 
disease activity in psoriatic arthritis?”.  For both of these questions, the majority of 
participants (88% and 93% respectively) voted no.  This provided clear support for the 
concept of a new composite disease activity measure for PsA as agreed upon at OMERACT 
10.  Some clinicians raised a concern with the concept of a composite score combining very 
different elements of one disease into a single score, and these may not respond similarly to a 
single therapy.  Disease activity in different domains of PsA may be unrelated, for example 
arthritis may flare when skin psoriasis is controlled or vice versa, and there are obviously 
different treatment implications depending on what element of the disease is active.   
 
However the potential benefit of such a composite score was also highlighted, particularly 
relevant to assessment of disease severity related to “qualifying” for certain treatment 
options.  Some patients may have moderate disease activity that by involving many different 
aspects of PsA may severely impact function and quality of life.  A composite score that 
accounts for all domains of psoriatic disease may better reflect such a patient’s disease 
burden.  It was agreed that a composite measure was an important research agenda for PsA, 
but it should be possible to identify the contributions of the individual domains to the total 
disease activity.  This could then guide clinicians in which therapy to choose. 
 
The advantage of all of these proposed composite measures is that they provide a numerical 
measure of disease activity state that can then be used to assess disease activity at one time 
point and can also be translated into response criteria defined by a minimum change in the 
score.  Potentially cut-offs for different levels of disease activity can also be defined and used 
to guide treatment decisions, acting as a target for treatment or a threshold for biologic 
therapies. 
 
A specific concern was raised regarding the methodology of the PASDAS. In the PASDAS, a 
measure of quality of life was included besides more specific disease activity measures.  This 
is in contrast to the DAS and ASDAS, similarly developed measures, which do not include 
quality of life domains and which only have one concept (peripheral joint disease or spinal 
disease respectively) assessed within each score, although inclusion of such data have been 
previously proposed in RCTs in SLE. It was questioned whether this methodology could then 
be used to develop the PASDAS if such different concepts were being combined. 
 
In terms of future planning, it was discussed that the PsA OMERACT group had exercises 
proposed to engage with patient research partners for further development of these composite 
measures and also in qualitative research to ensure that their views of disease activity and 
assessment are included. 
 
Finally the feasibility of such a composite score, particularly in routine clinical care, was 
discussed.  There are two key feasibility issues with the proposed composite measures.  The 
first is a potential problem for the PASDAS and AMDF related to the complexity of 
calculating the scores once all of the assessments have been done.  Both of these require 
statistical transformations of all of the variables with complex equations.  However all of this 
could be done using a simple spreadsheet or calculator such as those used for the RA DAS..  
The larger feasibility problem affecting all of these proposed scoring systems is the necessity 
to perform a number of different articular and non-articular outcome assessments to allow 
calculation of the scores.  This has implications on training of rheumatologists and 
dermatologists to perform these assessments and significant time implications initially if such 
a scoring system were to be introduced to clinical practice.   
 
At the end of the module and at the final plenary of the OMERACT meeting, a consensus 
voting exercise was held with all participants to gain agreement on future directions of the 
PsA OMERACT group.  The first two questions related to skin disease assessment.  When 
asked “Given that the skin is such an important component of psoriatic arthritis, should this 
domain be part of a composite index?” the majority (77%) of participants agreed that skin 
disease should be included.  They were then asked “Is it sufficient to assume that the patient 
and physician will take into account the skin component when determining the global disease 
assessment?”.  There was a lower agreement to this question, but 62% of patients felt that this 
could not be assumed.  As discussed above, there was concern about feasibility relating to 
composite indices, with 67% of participants feeling that it was “feasible to assess all clinical 
domains in a composite disease activity and responder index for psoriatic disease”.  The final 
questions related to the three proposed composite indices presented.  There was agreement 
(PASDAS – 78%, AMDF – 67%, CPDAI – 77%) that the further exploration and validation 
of all of these composite measures was appropriate to continue to investigate.  None of them 
however were at the stage of being proposed for adoption.  Further validation within existing 
datasets is planned as well as exercises with patients.    
 
Conclusion 
This module provided a valuable opportunity to present and discuss work on potential 
composite measures in PsA in a forum for discussion.  Three have been proposed but further 
validation and comparison in other datasets, such as those from existing and future 
interventional studies, is required. 
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Table 1 – Summary of current composite measures 
 
 DAS28 PsAJAI DAPSA CPDAI PASDAS AMDF 
Arthritis (joint counts) 28 66/68 66/68 66/68 66/68 66/68 
Skin disease N N N Y N N 
Enthesitis N N N Y Y N 
Dactylitis N N N Y Y N 
Spinal Disease N N N Y N N 
Health related quality of 
life 
N N N Y Y Y 
Physical function N Y N Y N Y 
Patient’s arthritis disease 
activity assessment 
N N N N N Y 
Patient’s skin disease 
activity assessment 
N N N N N Y 
Patient’s global disease 
activity assessment 
Y Y Y N Y Y 
Patient’s pain assessment N Y Y N N N 
Physician’s global disease 
activity assessment 
N Y N N Y N 
Acute phase response Y Y Y N Y N 
 
Table 2 – Example Case 1 
Element Score CPDAI score PASDAS score AMDF score 
TJC 0 0 
 
0 1 
SJC 0 0 1 
HAQ 0.4 
2 
- 0.84 
LEI 5 0.41 - 
Dactylitis 0 0 0 - 
PASI 8 
2 
- - 
DLQI 13 - - 
BASDAI 5.6 
3 
- - 
ASQoL 14 - - 
PsAQoL 9 - - 0.52 
SF36-PCS 30 - 1.39 0.27 
VAS patient 
global activity 
65 - 1.28 0.28 
VAS patient skin 
disease activity 
10 - - 0.8 
VAS patient joint 
disease activity 
35 - - 0.58 
VAS physician 
global activity 
60 - 1.39 - 
CRP 25 - 0.33 - 
TJC – tender joint count, SJC – swollen joint count, HAQ – health assessment questionnaire, 
LEI – Leeds enthesitis index, PASI – psoriasis area and severity index, DLQI – dermatology 
life quality index, BASDAI – Bath ankylosing spondylitis disease activity index, ASQoL – 
ankylosing spondylitis quality of life, PsAQoL – PsA quality of life, SF36-PCS – physical 
component score of short form 36, VAS – visual analogue scale, CRP – C-reactive protein 
 
Table 3 – Example Case 2  
Element Score CPDAI score PASDAS score AMDF score 
TJC 13 
3 
0.13 0.37 
SJC 11 0.12 0.36 
HAQ 0.88 
0 
- 0.67 
LEI 0 0 - 
Dactylitis 4 3 0.60 - 
PASI 2.3 
2 
- 0.82 
DLQI 12 - - 
BASDAI 2.16 
2 
- - 
ASQoL 15 - - 
PsAQoL 17 - - 0.14 
SF36-PCS 30.06 - 1.39 - 
VAS patient 
global activity 
65 - 1.28 0.28 
VAS patient skin 
disease activity 
10 - - 0.8 
VAS patient joint 
disease activity 
65 - - 0.28 
VAS physician 
global activity 
65 - 1.45 0.28 
CRP 24.7 - 0.33 - 
TJC – tender joint count, SJC – swollen joint count, HAQ – health assessment questionnaire, 
LEI – Leeds enthesitis index, PASI – psoriasis area and severity index, DLQI – dermatology 
life quality index, BASDAI – Bath ankylosing spondylitis disease activity index, ASQoL – 
ankylosing spondylitis quality of life, PsAQoL – PsA quality of life, SF36-PCS – physical 
component score of short form 36, VAS – visual analogue scale, CRP – C-reactive protein 
 
Table 4 – Example Case 3 
Element Score CPDAI score PASDAS score AMDF score 
TJC 2 
1 
0.05 0.8 
SJC 2 0.11 0.72 
HAQ 0.25 
1 
- 0.9 
LEI 2  0.25 - 
Dactylitis 2 1 0.41 - 
PASI 0 
0 
- 1 
DLQI 0 - - 
BASDAI 0.64 
0 
- - 
ASQoL 0 - - 
PsAQoL 1 - - 0.93 
SF36-PCS 46.84 - 1.73 - 
VAS patient 
global activity 
15 - 0.62 0.86 
VAS patient skin 
disease activity 
0 - - 1 
VAS patient joint 
disease activity 
16 - - 0.75 
VAS physician 
global activity 
7 - 0.48 0.8 
CRP 18 - 0.30 - 
TJC – tender joint count, SJC – swollen joint count, HAQ – health assessment questionnaire, 
LEI – Leeds enthesitis index, PASI – psoriasis area and severity index, DLQI – dermatology 
life quality index, BASDAI – Bath ankylosing spondylitis disease activity index, ASQoL – 
ankylosing spondylitis quality of life, PsAQoL – PsA quality of life, SF36-PCS – physical 
component score of short form 36, VAS – visual analogue scale, CRP – C-reactive protein 
 
 
